Corrigendum: Cross-resistance among sequential cancer therapeutics: An emerging issue

Front Oncol. 2022 Oct 31:12:1063651. doi: 10.3389/fonc.2022.1063651. eCollection 2022.

¹ Cellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
² Unit of Phase IV Trials, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
³ Medical Oncology A, Department of Radiological, Oncological, and Anatomo-Pathological Sciences, Umberto I University Hospital, University Sapienza, Rome, Italy.
⁴ Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.877380.].

Keywords: cancer therapeutics resistance; cross-resistance; personalized oncology; sequential therapeutics; targeted-therapy.